お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、モノクローナル抗体の世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にモノクローナル抗体市場を分類しています。
本レポートでは世界のモノクローナル抗体市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Celltrion、Pfizer (Hospira)、3SBIO、Novartis (Sandoz)、Dr Reddy’s、Celgen Biopharma、Cadila Healthcare、Hisun Pharma、Torrent Pharmaceuticals、Fresenius Kabi、Coherus Solutions、Biogen、Amgen、Biocon Biologics、Organon

レポートはモノクローナル抗体の主要生産者を調査し、主要地域や国の消費状況も提供します。モノクローナル抗体の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Infliximab
    Rituximab
    Trastuzumab
    Adalimumab
    Other

用途別の市場セグメント：
    Oncology
    Autoimmune Disease
    Other

本レポートの詳細内容
本レポートは、世界のモノクローナル抗体市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてモノクローナル抗体市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）のモノクローナル抗体生産量、成長率、市場シェアを調査している。

二. 消費面では、モノクローナル抗体の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーのモノクローナル抗体売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のモノクローナル抗体市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本モノクローナル抗体のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：モノクローナル抗体のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： モノクローナル抗体の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおけるモノクローナル抗体の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章モノクローナル抗体メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：モノクローナル抗体の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：モノクローナル抗体の主要メーカーの概要を提供し、製品の説明と仕様、モノクローナル抗体の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：モノクローナル抗体の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies. Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
The global Biosimilar Monoclonal Antibodies market is projected to grow from US$ 6087 million in 2024 to US$ 14830 million by 2030, at a Compound Annual Growth Rate (CAGR) of 16.0% during the forecast period.
The biosimilar monoclonal antibodies market is primarily driven by the increasing demand for cost-effective biologic treatments. As patents for many original biologic drugs expire, biosimilars offer a more affordable alternative without compromising efficacy. This is particularly important in treating chronic diseases like cancer and autoimmune disorders, where long-term treatment costs can be prohibitive. The growing acceptance of biosimilars by healthcare providers and regulatory approvals in various regions further propels market growth. However, a key challenge facing the market is the complexity of manufacturing biosimilar monoclonal antibodies. Due to their structural intricacies, even minor variations in production processes can lead to differences in efficacy or safety compared to the original biologic. Additionally, patient and physician skepticism, driven by concerns over efficacy and potential side effects, can hinder widespread adoption, especially in markets where the original biologics are well-established. Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis, etc. Global top four manufacturers hold a share nearly 85%. Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.  In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
Report Includes
This report presents an overview of global market for Biosimilar Monoclonal Antibodies, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biosimilar Monoclonal Antibodies, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Biosimilar Monoclonal Antibodies, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biosimilar Monoclonal Antibodies sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biosimilar Monoclonal Antibodies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biosimilar Monoclonal Antibodies sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr Reddy’s, Celgen Biopharma, Cadila Healthcare, Hisun Pharma, Torrent Pharmaceuticals, Fresenius Kabi, etc.

Market Segmentation
By Company
    Celltrion
    Pfizer (Hospira)
    3SBIO
    Novartis (Sandoz)
    Dr Reddy’s
    Celgen Biopharma
    Cadila Healthcare
    Hisun Pharma
    Torrent Pharmaceuticals
    Fresenius Kabi
    Coherus Solutions
    Biogen
    Amgen
    Biocon Biologics
    Organon

Segment by Type
    Infliximab
    Rituximab
    Trastuzumab
    Adalimumab
    Other

Segment by Application
    Oncology
    Autoimmune Disease
    Other

Segment by region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia

Middle East, Africa, Latin America
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Biosimilar Monoclonal Antibodies in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilar Monoclonal Antibodies sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
 Table 1. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Table 2. Major Manufacturers of Infliximab
 Table 3. Major Manufacturers of Rituximab
 Table 4. Major Manufacturers of Trastuzumab
 Table 5. Major Manufacturers of Adalimumab
 Table 6. Major Manufacturers of Other
 Table 7. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Table 8. Global Biosimilar Monoclonal Antibodies Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 9. Global Biosimilar Monoclonal Antibodies Revenue by Region (2019-2024) & (US$ Million)
 Table 10. Global Biosimilar Monoclonal Antibodies Revenue by Region (2025-2030) & (US$ Million)
 Table 11. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2019-2024)
 Table 12. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2025-2030)
 Table 13. Global Biosimilar Monoclonal Antibodies Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
 Table 14. Global Biosimilar Monoclonal Antibodies Sales by Region (2019-2024) & (K Units)
 Table 15. Global Biosimilar Monoclonal Antibodies Sales by Region (2025-2030) & (K Units)
 Table 16. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2019-2024)
 Table 17. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2025-2030)
 Table 18. Global Biosimilar Monoclonal Antibodies Sales by Manufacturers (2019-2024) & (K Units)
 Table 19. Global Biosimilar Monoclonal Antibodies Sales Share by Manufacturers (2019-2024)
 Table 20. Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2019-2024) & (US$ Million)
 Table 21. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2019-2024)
 Table 22. Global Key Players of Biosimilar Monoclonal Antibodies, Industry Ranking, 2021 VS 2022 VS 2023
 Table 23. Biosimilar Monoclonal Antibodies Price by Manufacturers (2019-2024) & (US$/Unit)
 Table 24. Global Biosimilar Monoclonal Antibodies Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 25. Global Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Monoclonal Antibodies as of 2023)
 Table 26. Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Base Distribution and Headquarters
 Table 27. Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Product Offered and Application
 Table 28. Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Date of Enter into This Industry
 Table 29. Mergers & Acquisitions, Expansion Plans
 Table 30. Global Biosimilar Monoclonal Antibodies Sales by Type (2019-2024) & (K Units)
 Table 31. Global Biosimilar Monoclonal Antibodies Sales by Type (2025-2030) & (K Units)
 Table 32. Global Biosimilar Monoclonal Antibodies Sales Share by Type (2019-2024)
 Table 33. Global Biosimilar Monoclonal Antibodies Sales Share by Type (2025-2030)
 Table 34. Global Biosimilar Monoclonal Antibodies Revenue by Type (2019-2024) & (US$ Million)
 Table 35. Global Biosimilar Monoclonal Antibodies Revenue by Type (2025-2030) & (US$ Million)
 Table 36. Global Biosimilar Monoclonal Antibodies Revenue Share by Type (2019-2024)
 Table 37. Global Biosimilar Monoclonal Antibodies Revenue Share by Type (2025-2030)
 Table 38. Biosimilar Monoclonal Antibodies Price by Type (2019-2024) & (US$/Unit)
 Table 39. Global Biosimilar Monoclonal Antibodies Price Forecast by Type (2025-2030) & (US$/Unit)
 Table 40. Global Biosimilar Monoclonal Antibodies Sales by Application (2019-2024) & (K Units)
 Table 41. Global Biosimilar Monoclonal Antibodies Sales by Application (2025-2030) & (K Units)
 Table 42. Global Biosimilar Monoclonal Antibodies Sales Share by Application (2019-2024)
 Table 43. Global Biosimilar Monoclonal Antibodies Sales Share by Application (2025-2030)
 Table 44. Global Biosimilar Monoclonal Antibodies Revenue by Application (2019-2024) & (US$ Million)
 Table 45. Global Biosimilar Monoclonal Antibodies Revenue by Application (2025-2030) & (US$ Million)
 Table 46. Global Biosimilar Monoclonal Antibodies Revenue Share by Application (2019-2024)
 Table 47. Global Biosimilar Monoclonal Antibodies Revenue Share by Application (2025-2030)
 Table 48. Biosimilar Monoclonal Antibodies Price by Application (2019-2024) & (US$/Unit)
 Table 49. Global Biosimilar Monoclonal Antibodies Price Forecast by Application (2025-2030) & (US$/Unit)
 Table 50. US & Canada Biosimilar Monoclonal Antibodies Sales by Type (2019-2024) & (K Units)
 Table 51. US & Canada Biosimilar Monoclonal Antibodies Sales by Type (2025-2030) & (K Units)
 Table 52. US & Canada Biosimilar Monoclonal Antibodies Revenue by Type (2019-2024) & (US$ Million)
 Table 53. US & Canada Biosimilar Monoclonal Antibodies Revenue by Type (2025-2030) & (US$ Million)
 Table 54. US & Canada Biosimilar Monoclonal Antibodies Sales by Application (2019-2024) & (K Units)
 Table 55. US & Canada Biosimilar Monoclonal Antibodies Sales by Application (2025-2030) & (K Units)
 Table 56. US & Canada Biosimilar Monoclonal Antibodies Revenue by Application (2019-2024) & (US$ Million)
 Table 57. US & Canada Biosimilar Monoclonal Antibodies Revenue by Application (2025-2030) & (US$ Million)
 Table 58. US & Canada Biosimilar Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 59. US & Canada Biosimilar Monoclonal Antibodies Revenue by Country (2019-2024) & (US$ Million)
 Table 60. US & Canada Biosimilar Monoclonal Antibodies Revenue by Country (2025-2030) & (US$ Million)
 Table 61. US & Canada Biosimilar Monoclonal Antibodies Sales by Country (2019-2024) & (K Units)
 Table 62. US & Canada Biosimilar Monoclonal Antibodies Sales by Country (2025-2030) & (K Units)
 Table 63. Europe Biosimilar Monoclonal Antibodies Sales by Type (2019-2024) & (K Units)
 Table 64. Europe Biosimilar Monoclonal Antibodies Sales by Type (2025-2030) & (K Units)
 Table 65. Europe Biosimilar Monoclonal Antibodies Revenue by Type (2019-2024) & (US$ Million)
 Table 66. Europe Biosimilar Monoclonal Antibodies Revenue by Type (2025-2030) & (US$ Million)
 Table 67. Europe Biosimilar Monoclonal Antibodies Sales by Application (2019-2024) & (K Units)
 Table 68. Europe Biosimilar Monoclonal Antibodies Sales by Application (2025-2030) & (K Units)
 Table 69. Europe Biosimilar Monoclonal Antibodies Revenue by Application (2019-2024) & (US$ Million)
 Table 70. Europe Biosimilar Monoclonal Antibodies Revenue by Application (2025-2030) & (US$ Million)
 Table 71. Europe Biosimilar Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 72. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2019-2024) & (US$ Million)
 Table 73. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2025-2030) & (US$ Million)
 Table 74. Europe Biosimilar Monoclonal Antibodies Sales by Country (2019-2024) & (K Units)
 Table 75. Europe Biosimilar Monoclonal Antibodies Sales by Country (2025-2030) & (K Units)
 Table 76. China Biosimilar Monoclonal Antibodies Sales by Type (2019-2024) & (K Units)
 Table 77. China Biosimilar Monoclonal Antibodies Sales by Type (2025-2030) & (K Units)
 Table 78. China Biosimilar Monoclonal Antibodies Revenue by Type (2019-2024) & (US$ Million)
 Table 79. China Biosimilar Monoclonal Antibodies Revenue by Type (2025-2030) & (US$ Million)
 Table 80. China Biosimilar Monoclonal Antibodies Sales by Application (2019-2024) & (K Units)
 Table 81. China Biosimilar Monoclonal Antibodies Sales by Application (2025-2030) & (K Units)
 Table 82. China Biosimilar Monoclonal Antibodies Revenue by Application (2019-2024) & (US$ Million)
 Table 83. China Biosimilar Monoclonal Antibodies Revenue by Application (2025-2030) & (US$ Million)
 Table 84. Asia Biosimilar Monoclonal Antibodies Sales by Type (2019-2024) & (K Units)
 Table 85. Asia Biosimilar Monoclonal Antibodies Sales by Type (2025-2030) & (K Units)
 Table 86. Asia Biosimilar Monoclonal Antibodies Revenue by Type (2019-2024) & (US$ Million)
 Table 87. Asia Biosimilar Monoclonal Antibodies Revenue by Type (2025-2030) & (US$ Million)
 Table 88. Asia Biosimilar Monoclonal Antibodies Sales by Application (2019-2024) & (K Units)
 Table 89. Asia Biosimilar Monoclonal Antibodies Sales by Application (2025-2030) & (K Units)
 Table 90. Asia Biosimilar Monoclonal Antibodies Revenue by Application (2019-2024) & (US$ Million)
 Table 91. Asia Biosimilar Monoclonal Antibodies Revenue by Application (2025-2030) & (US$ Million)
 Table 92. Asia Biosimilar Monoclonal Antibodies Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 93. Asia Biosimilar Monoclonal Antibodies Revenue by Region (2019-2024) & (US$ Million)
 Table 94. Asia Biosimilar Monoclonal Antibodies Revenue by Region (2025-2030) & (US$ Million)
 Table 95. Asia Biosimilar Monoclonal Antibodies Sales by Region (2019-2024) & (K Units)
 Table 96. Asia Biosimilar Monoclonal Antibodies Sales by Region (2025-2030) & (K Units)
 Table 97. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales by Type (2019-2024) & (K Units)
 Table 98. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales by Type (2025-2030) & (K Units)
 Table 99. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue by Type (2019-2024) & (US$ Million)
 Table 100. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue by Type (2025-2030) & (US$ Million)
 Table 101. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales by Application (2019-2024) & (K Units)
 Table 102. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales by Application (2025-2030) & (K Units)
 Table 103. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue by Application (2019-2024) & (US$ Million)
 Table 104. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue by Application (2025-2030) & (US$ Million)
 Table 105. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 106. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2024) & (US$ Million)
 Table 107. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2025-2030) & (US$ Million)
 Table 108. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales by Country (2019-2024) & (K Units)
 Table 109. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales by Country (2025-2030) & (K Units)
 Table 110. Celltrion Company Information
 Table 111. Celltrion Description and Major Businesses
 Table 112. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Celltrion Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 114. Celltrion Recent Developments
 Table 115. Pfizer (Hospira) Company Information
 Table 116. Pfizer (Hospira) Description and Major Businesses
 Table 117. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 119. Pfizer (Hospira) Recent Developments
 Table 120. 3SBIO Company Information
 Table 121. 3SBIO Description and Major Businesses
 Table 122. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. 3SBIO Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 124. 3SBIO Recent Developments
 Table 125. Novartis (Sandoz) Company Information
 Table 126. Novartis (Sandoz) Description and Major Businesses
 Table 127. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 129. Novartis (Sandoz) Recent Developments
 Table 130. Dr Reddy’s Company Information
 Table 131. Dr Reddy’s Description and Major Businesses
 Table 132. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Dr Reddy’s Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 134. Dr Reddy’s Recent Developments
 Table 135. Celgen Biopharma Company Information
 Table 136. Celgen Biopharma Description and Major Businesses
 Table 137. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 138. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 139. Celgen Biopharma Recent Developments
 Table 140. Cadila Healthcare Company Information
 Table 141. Cadila Healthcare Description and Major Businesses
 Table 142. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 143. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 144. Cadila Healthcare Recent Developments
 Table 145. Hisun Pharma Company Information
 Table 146. Hisun Pharma Description and Major Businesses
 Table 147. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 148. Hisun Pharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 149. Hisun Pharma Recent Developments
 Table 150. Torrent Pharmaceuticals Company Information
 Table 151. Torrent Pharmaceuticals Description and Major Businesses
 Table 152. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 153. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 154. Torrent Pharmaceuticals Recent Developments
 Table 155. Fresenius Kabi Company Information
 Table 156. Fresenius Kabi Description and Major Businesses
 Table 157. Fresenius Kabi Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 158. Fresenius Kabi Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 159. Fresenius Kabi Recent Developments
 Table 160. Coherus Solutions Company Information
 Table 161. Coherus Solutions Description and Major Businesses
 Table 162. Coherus Solutions Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 163. Coherus Solutions Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 164. Coherus Solutions Recent Developments
 Table 165. Biogen Company Information
 Table 166. Biogen Description and Major Businesses
 Table 167. Biogen Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 168. Biogen Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 169. Biogen Recent Developments
 Table 170. Amgen Company Information
 Table 171. Amgen Description and Major Businesses
 Table 172. Amgen Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 173. Amgen Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 174. Amgen Recent Developments
 Table 175. Biocon Biologics Company Information
 Table 176. Biocon Biologics Description and Major Businesses
 Table 177. Biocon Biologics Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 178. Biocon Biologics Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 179. Biocon Biologics Recent Developments
 Table 180. Organon Company Information
 Table 181. Organon Description and Major Businesses
 Table 182. Organon Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 183. Organon Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
 Table 184. Organon Recent Developments
 Table 185. Key Raw Materials Lists
 Table 186. Raw Materials Key Suppliers Lists
 Table 187. Biosimilar Monoclonal Antibodies Distributors List
 Table 188. Biosimilar Monoclonal Antibodies Customers List
 Table 189. Biosimilar Monoclonal Antibodies Market Trends
 Table 190. Biosimilar Monoclonal Antibodies Market Drivers
 Table 191. Biosimilar Monoclonal Antibodies Market Challenges
 Table 192. Biosimilar Monoclonal Antibodies Market Restraints
 Table 193. Research Programs/Design for This Report
 Table 194. Key Data Information from Secondary Sources
 Table 195. Key Data Information from Primary Sources


List of Figures
 Figure 1. Biosimilar Monoclonal Antibodies Product Picture
 Figure 2. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Biosimilar Monoclonal Antibodies Market Share by Type: 2023 & 2030
 Figure 4. Infliximab Product Picture
 Figure 5. Rituximab Product Picture
 Figure 6. Trastuzumab Product Picture
 Figure 7. Adalimumab Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 10. Global Biosimilar Monoclonal Antibodies Market Share by Application: 2023 & 2030
 Figure 11. Oncology
 Figure 12. Autoimmune Disease
 Figure 13. Other
 Figure 14. Biosimilar Monoclonal Antibodies Report Years Considered
 Figure 15. Global Biosimilar Monoclonal Antibodies Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 16. Global Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 17. Global Biosimilar Monoclonal Antibodies Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Figure 18. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region in Percentage: 2023 Versus 2030
 Figure 19. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2019-2030)
 Figure 20. Global Biosimilar Monoclonal Antibodies Sales (2019-2030) & (K Units)
 Figure 21. Global Biosimilar Monoclonal Antibodies Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
 Figure 22. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2019-2030)
 Figure 23. US & Canada Biosimilar Monoclonal Antibodies Sales YoY (2019-2030) & (K Units)
 Figure 24. US & Canada Biosimilar Monoclonal Antibodies Revenue YoY (2019-2030) & (US$ Million)
 Figure 25. Europe Biosimilar Monoclonal Antibodies Sales YoY (2019-2030) & (K Units)
 Figure 26. Europe Biosimilar Monoclonal Antibodies Revenue YoY (2019-2030) & (US$ Million)
 Figure 27. China Biosimilar Monoclonal Antibodies Sales YoY (2019-2030) & (K Units)
 Figure 28. China Biosimilar Monoclonal Antibodies Revenue YoY (2019-2030) & (US$ Million)
 Figure 29. Asia (excluding China) Biosimilar Monoclonal Antibodies Sales YoY (2019-2030) & (K Units)
 Figure 30. Asia (excluding China) Biosimilar Monoclonal Antibodies Revenue YoY (2019-2030) & (US$ Million)
 Figure 31. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales YoY (2019-2030) & (K Units)
 Figure 32. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue YoY (2019-2030) & (US$ Million)
 Figure 33. Global Biosimilar Monoclonal Antibodies Sales Share by Manufacturers (2023)
 Figure 34. The Biosimilar Monoclonal Antibodies Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
 Figure 35. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2023)
 Figure 36. The Top 5 and 10 Largest Manufacturers of Biosimilar Monoclonal Antibodies in the World: Market Share by Biosimilar Monoclonal Antibodies Revenue in 2023
 Figure 37. Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 38. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2030)
 Figure 39. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
 Figure 40. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2030)
 Figure 41. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
 Figure 42. US & Canada Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2030)
 Figure 43. US & Canada Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
 Figure 44. US & Canada Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2030)
 Figure 45. US & Canada Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
 Figure 46. US & Canada Biosimilar Monoclonal Antibodies Revenue Share by Country (2019-2030)
 Figure 47. US & Canada Biosimilar Monoclonal Antibodies Sales Share by Country (2019-2030)
 Figure 48. US Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 49. Canada Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 50. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2030)
 Figure 51. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
 Figure 52. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2030)
 Figure 53. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
 Figure 54. Europe Biosimilar Monoclonal Antibodies Revenue Share by Country (2019-2030)
 Figure 55. Europe Biosimilar Monoclonal Antibodies Sales Share by Country (2019-2030)
 Figure 56. Germany Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 57. France Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 58. U.K. Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 59. Italy Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 60. Russia Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 61. China Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2030)
 Figure 62. China Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
 Figure 63. China Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2030)
 Figure 64. China Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
 Figure 65. Asia Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2030)
 Figure 66. Asia Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
 Figure 67. Asia Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2030)
 Figure 68. Asia Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
 Figure 69. Asia Biosimilar Monoclonal Antibodies Revenue Share by Region (2019-2030)
 Figure 70. Asia Biosimilar Monoclonal Antibodies Sales Share by Region (2019-2030)
 Figure 71. Japan Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 72. South Korea Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 73. China Taiwan Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 74. Southeast Asia Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 75. India Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 76. Australia Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 77. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2030)
 Figure 78. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
 Figure 79. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2030)
 Figure 80. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
 Figure 81. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Revenue Share by Country (2019-2030)
 Figure 82. Middle East, Africa and Latin America Biosimilar Monoclonal Antibodies Sales Share by Country (2019-2030)
 Figure 83. Brazil Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 84. Mexico Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 85. Turkey Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 86. Israel Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 87. GCC Countries Biosimilar Monoclonal Antibodies Revenue (2019-2030) & (US$ Million)
 Figure 88. Biosimilar Monoclonal Antibodies Value Chain
 Figure 89. Biosimilar Monoclonal Antibodies Production Process
 Figure 90. Channels of Distribution (Direct Vs Distribution)
 Figure 91. Bottom-up and Top-down Approaches for This Report
 Figure 92. Data Triangulation
 Figure 93. Key Executives Interviewed